Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study – The Lancet Haematology

Commentaries:

CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)

CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)

Commentary on Twitter

NEW research—tisagenlecleucel has antitumour activity and acceptable safety in young children and infants (aged younger than 3 years at screening) with B-cell ALL: results of an international, retrospective study #leusm #pedonc #tcellrx https://t.co/kdh3dW5PRU pic.twitter.com/FgQZKQWtXV

— The Lancet Haematology (@TheLancetHaem) September 8, 2022